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Fig.    Figure 
FTIR    Fourier transform Infra Red 
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min    Minutes 
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pH 
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FDT    fastly  Disintegrating Tablet 
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rpm    Rotations per minute 
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1. INTRODUCTION 
 
Fast-disintegrating and fast-dissolving tablets are becoming popular as novel delivery 
systems for drug administration. They are more convenient for children, elderly patients, 
patients with swallowing difficulties, and in the absence of potable liquids. The most 
desirable formulation for use by the elderly is one that is easy to swallow easy to handle. 
Taking these requirements into consideration, attempts have been made to develop a fast-
disintegrating tablet. Since such a tablet can disintegrate in only a small amount of water in 
the oral cavity, it is easy to take for any age patient, regardless of time or place. For example, 
it can be taken anywhere at anytime by anyone who do not have easy access to water. It is 
also easy to dose the aged, bed-ridden patients, or infants who have problems swallowing 
tablets and capsules. Recently, many companies have researched and developed various 
types of fast-disintegrating dosage forms.1 
These tablets display a fast and spontaneous de-aggregation in the mouth, soon after 
the contact with saliva, though they can be handled or extracted from the package without 
alteration. The active agent can thus rapidly dissolve in the saliva and be absorbed through 
whatever membrane it encounters, during deglutition, unless it is protected from pre-gastric 
absorption. To fulfill these requirements, tablets must be highly porous, incorporating 
hydrophilic excipients, able to rapidly absorb water for a rapid deaggregation of the matrix. 
Different technological techniques, such as freeze drying or moulding or direct compression 
are currently employed to prepare the formulations of this type present on the pharmaceutical 
market. 
Honda and Nakano reported that a half of the patients surveyed experienced difficulty 
in taking medication and felt that a tablet was a better and easier formulation compared to 
other formulations such as capsules or powders. Sugihara reported that the degree of ease 
when taking a tablet depended on its size. He reported that the size of tablet that was easiest 
to swallow was 7–8 mm, but the size easiest to handle was one larger than 8 mm. 
 
1.1. Advantages of Fast Disintegrating Drug Delivery System (FDDS) 1-3 
1. Ease of administration to patients who refuse to swallow a tablet, such as pediatric and 
geriatric patients, mentally ill, disabled and uncooperative. 
2. Convenience of administration and accurate dosing as compared to liquids.  
3. No need of water to swallow the dosage from, which is highly convenient feature for 
patients who are traveling and do not have immediate access to water. 
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4. Good mouth feel property of FDDS helps to change the basic view of medication as 
"bitter pill", particularly for pediatric patients. 
5. Ability to provide advantages of liquid medication in the form of solid preparation. 
6. Rapid dissolution of drug and absorption, which may produce rapid onset of action. 
7. Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes 
down into the stomach; in such cases bioavailability of drugs is increased. 
8. Ability to provide advantages of liquid medication in the form of solid preparation. 
9. Pregastric absorption can result in improved bioavailability and as a result of reduced 
dosage, improved clinical performance through a reduction of unwanted effects. 
 
1.2. Characteristics of fast disintegrating systems 2-5 
a. Ease of administration 
Fast disintegrating drug delivery Systems are easy to administer and handle hence, 
leads to better patient compliance. Usually, elderly people experience difficulty in 
swallowing the conventional dosage forms (Tablets, capsules, solutions and suspensions) 
because of tremors of extremities and dysphasia. Fast Dissolving Delivery Systems may 
offer a solution for these problems.  
 
b. Taste of the medicament 
As most drugs are unpalatable, fast disintegrating drug delivery systems usually 
contain the medicament in taste masked form. These delivery systems dissolve or 
disintegrate in patient’s mouth, thus releasing the active ingredients which come in contact 
with the taste buds and hence, taste masking of the drugs becomes critical to patient 
compliance. 
 
c. Hygroscopicity 
Several fast dissolving dosage forms are hygroscopic and cannot maintain physical 
integrity under normal condition from humidity which calls for specialized product 
packaging.    
 
 d. Friability 
In order to allow fast disintegrating  tablets to dissolve in the mouth, they are made of 
either very porous and soft- moulded matrices or compressed into tablets with very low 
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compression force, which makes the tablets friable and/or brittle which are difficult to 
handle, often requiring specialized peel-off blister packaging.  
e. Mouth feel 
Mouth feel is critical, and patients should receive a product that feels pleasant. Any 
large particles from the disintegrating tablet that are insoluble or slowly soluble in saliva 
would lead to an unpleasant gritty feeling. This can be overcome by keeping the majority of 
the particles below the detectable size limit. In some cases, certain flavors can imbibe an 
improved mouth feel perception, resulting in a product that is perceived as being less gritty, 
even if the only change is the flavor. Effervescence can be added to aid disintegration and 
improve mouth feel by reducing the “dryness” of a product. 
 
Table No: 1 Various therapeutic areas in which the fast disintegrating  
               dosage forms are available 
Target population Therapeutic areas 
 
Pediatric 
Antibiotics 
 Anti-asthmatics 
Cough/Cold/Allergy 
 Anti-epileptics 
Analgesics/Antipyretics 
 Antidepressants 
 
 
Adult & Elderly 
Parkinson’s 
Antimigraine 
Alzheimer’s 
 Anti-emetics 
Cancer 
Diabetes 
AIDS 
Gastric Relief 
Psychotherapeutics 
 Cardiovascular 
Cough/Cold/Allergy 
Analgesics/NSAIDS 
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1.3. Approaches for fast disintegrating tablets 2-6 
A. Patented technologies                                                                                    
Currently, four fast-dissolving/disintegrating technologies have reached the U.S. market:  
1) Zydis (R.P. Scherer, Inc.) 
2) WOWTAB (Yamanouchi Pharma Technologies, Inc.) 
3) OraSolv (Cima Labs, Inc.) 
4) DuraSolv (Cima Labs, Inc.) 
 
B. Three others are available outside the U.S.   
1) Flash Dose (Fuisz Technologies, Ltd.),  
2) Flash tab (Prographarm Group),  
3) OraQuick (KV Pharmaceutical Co., Inc.)  
4) Nanocrystal Technology 
 
C. Conventional technologies 
1.Freeze –drying or lyophilization 
2. Tablet Molding 
3. Direct compression 
4. Spray drying 
5. Sublimation 
6. Mass extrusion 
 
A. Patented technologies 
1. Zydis technology  
Zydis the best known of the fast-dissolving/disintegrating tablet preparations was the 
first marketed new technology tablet. The tablet dissolves in the mouth within seconds after 
placement on the tongue. A Zydis tablet is produced by lyophilizing or freeze-drying the 
drug in a matrix usually consisting of gelatin. The product is very lightweight and fragile, 
and must be dispensed in a special blister pack. Patients should be advised not to push the 
tablets through the foil film, but instead peel the film back to release the tablet. The Zydis 
product is made to dissolve on the tongue in 2 to 3 seconds. The Zydis formulation is also 
self-preserving because the final water concentration in the freeze-dried product is too low to 
allow for microbial growth. A major claim of the Zydis product is increased bioavailability 
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compared to traditional tablets. Because of its dispersion and dissolution in saliva while still 
in the oral cavity, there can be a substantial amount of pregastric absorption from this 
formulation. Buccal, pharyngeal and gastric regions are all areas of absorption of the Zydis 
formulation. Any pre-gastric absorption avoids first-pass metabolism and can be an 
advantage in drugs that undergo a great deal of hepatic metabolism. However, if the amount 
of swallowed drug varies, there is the potential for inconsistent bioavailability. While the 
claimed increase in bioavailability is debatable, it is clear that the major advantage of the 
Zydis formulation is convenience. The amount of drug that could be incorporated should 
generally be less than 60 mg for soluble drugs. The partical size of the insoluble drugs 
should be less than 50mm and not more than 200mm to prevent sedimentation during 
processing. There are some disadvantages to the Zydis technology. The process of freeze-
drying is a relatively expensive manufacturing process. As mentioned earlier, the Zydis 
formulation is very lightweight and fragile, and therefore should not be stored in backpacks 
or the bottom of purses. Finally, the Zydis formulation has poor stability at higher 
temperatures and humidities. It readily absorbs water, and is very sensitive to degradation at 
humidities greater than 65%. 
 
2. Wowtab technology  
The Wowtab fast-dissolving/disintegrating tablet formulation has been on the 
Japanese market for a number of years.  Wowtab technology is patented by Yamanouchi 
Pharmaceutical Co. The WOW in Wowtab signifies the tablet is to be given “With out 
Water”. It has just recently been introduced into the U.S. The Wowtab technology utilizes 
sugar and sugar-like (e.g; mannitol) excipients. This process uses a combination of low 
mouldability saccharides (rapid dissolution) and high mouldability saccharide (good binding 
property).The two different types of saccharides are combined to obtain a tablet formulation 
with adequate hardness and fast dissolution rate. Due to its significant hardness, the Wowtab 
formulation is a bit more stable to the environment than the Zydis or OraSolv. It is suitable 
for both conventional bottle and blister packaging. The taste masking technology utilized in 
the Wowtab is proprietary, but claims to offer superior mouth feel due to the patented 
smooth melt action. The Wowtab product dissolves quickly in 15 seconds or less. 
 
2. OraSolv technology 
OraSolv was Cima's first fast-dissolving/disintegrating dosage form. The OraSolv 
technology, unlike Zydis, disperses in the saliva with the aid of almost imperceptible 
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effervescence. The OraSolv technology is best described as a fast-disintegrating tablet; the 
tablet matrix dissolves in less than one minute, leaving coated drug powder. The taste 
masking associated with the OraSolv formulation is two-fold. The unpleasant flavor of a 
drug is not merely counteracted by sweeteners or flavors; both coating the drug powder and 
effervescence are means of taste masking in OraSolv. This technology is frequently used to 
develop over-the-counter formulations. The major disadvantage of the OraSolv formulations 
is its mechanical strength. The OraSolv tablet has the appearance of a traditional compressed 
tablet. However, the OraSolv tablets are only lightly compressed, yielding a weaker and 
more brittle tablet in comparison with conventional tablets. For that reason, Cima developed 
a special handling and packaging system for OraSolv. An advantage that goes along with the 
low degree of compaction of OraSolv is that the particle coating used for taste masking is not 
compromised by fracture during processing. Lyophilization and high degrees of 
compression, as utilized in OraSolv's primary competitors, may disrupt such a taste masking 
approach. The OraSolv technology is utilized in six marketed products. These formulations 
can accommodate single or multiple active ingredients and tablets containing more that 1.0 g 
of drug have been developed. Their disintegration time is less than 30s.The OraSolv 
formulations are not very hygroscopic.  
 
3. DuraSolv technology  
DuraSolv is Cima's second-generation fast-dissolving/disintegrating tablet 
formulation. Produced in a fashion similar to OraSolv, DuraSolv has much higher 
mechanical strength than its predecessor due to the use of higher compaction pressures 
during tableting. DuraSolv tablets are prepared by using conventional tabletting equipment 
and have good rigidity (friability less than that 2%). The DuraSolv product is thus produced 
in a faster and more cost-effective manner. DuraSolv is so durable that it can be packaged in 
traditional blister packaging, pouches or vials. 
One disadvantage of DuraSolv is that the technology is not compatible with larger 
doses of active ingredients, because the formulation is subjected to such high pressures on 
compaction. Unlike OraSolv, the structural integrity of any taste masking may be 
compromised with high drug doses. The drug powder coating in DuraSolv may become 
fractured during compaction, exposing the bitter-tasting drug to a patient's taste buds. 
Therefore, the DuraSolv technology is best suited for formulations including relatively small 
doses of active compound.  
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B. Three others are available outside the U.S. 
1. Flash dose technology  
Fuisz Technologies has three oral drug delivery systems that are related to fast 
dissolution. The first two generations of quick-dissolving tablets, Soft Chew and EZ Chew, 
require some chewing. However, these paved the way for Fuisz's most recent development, 
Flash dose. The Flash dose technology utilizes a unique spinning mechanism to produce a 
floss-like crystalline structure, much like cotton candy. This crystalline sugar can then 
incorporate the active drug and be compressed into a tablet. This procedure has been 
patented by Fuisz and is known as Shearform. The final product has a very high surface area 
for dissolution. It disperses and dissolves quickly once placed onto the tongue.  
Flash dose tablets consist of self–binding shear form matrix termed as “floss”. Shear 
form matrices are prepared by flash heat processing and are of two types. Single floss or 
Unifloss, consisting of a carrier, and two or more sugar alcohols, of which one is xylitol. 
Dual floss consists of a first shear form carrier material (termed “base floss”, contains a 
carrier and at least one sugar alcohol generally sorbitol), and a second shear form binder 
matrix (“binder floss”, contains a carrier and xylitol). 
Interestingly, by changing the temperature and other conditions during production, 
the characteristics of the product can be altered greatly. Instead of a floss-like material, small 
spheres of saccharides can be produced to carry the drug. The process of making 
microspheres has been patented by Fuisz, and is known as CEFORM and serves as an 
alternative method of taste masking. 
  
2. Flash tab technology  
Prographarm laboratories have patented the Flashtab technology. This technology 
involves the preparation of rapidly disintegrating tablet which consists of an active ingredient 
in the form of microcystals. Drug microgranules may be prepared by using the conventional 
techniques like coacervation, extrusion-spheronization, simple pan coating methods and 
micro encapsulation. The microcrystals of microgranules of the active ingredient are added 
to the granulated mixture of excipients prepared by wet or dry granulation, and compressed 
into tablets. All the processing utilized the conventional tabletting technology, and the tablets 
produced are reported to have good mechanical strength and disintegration time less than one 
minute. 
 
 
Introduction 
Padmavathi College of Pharmacy and Research Institute  8 
 
3. OraQuick 
The OraQuick fast-dissolving/disintegrating tablet formulation utilizes a patented 
taste masking technology. KV Pharmaceutical claims its microsphere technology, known as 
MicroMask, has superior mouth feel over taste-masking alternatives. The taste masking 
process does not utilize solvents of any kind, and therefore leads to faster and more efficient 
production. Also, lower heat of production than alternative fast-dissolving/disintegrating 
technologies makes OraQuick appropriate for heat-sensitive drugs. KV Pharmaceutical also 
claims that the matrix that surrounds and protects the drug powder in microencapsulated 
particles is more pliable, meaning tablets can be compressed to achieve significant 
mechanical strength without disrupting taste masking. OraQuick claims quick dissolution in 
a matter of seconds, with good taste-masking. There are no products using the OraQuick 
technology currently on the market, but KV Pharmaceutical has products in development 
such as analgesics, scheduled drugs, cough and cold, Psycho tropics, and Anti-infectives. 
 
4. Nano Crystal technology 
For fast dissolving tablets, Elan's proprietary Nano Crystal technology can enable 
formulation and improve compound activity and final product characteristics. Decreasing 
particle size increases the surface area, which leads to an increase in dissolution rate. This 
can be accomplished predictably and efficiently using Nano Crystal technology. Nano 
Crystal particles are small particles of drug substance, typically less than 1000 nanometers 
(nm) in diameter, which are produced by milling the drug substance using a proprietary wet 
milling technique. 
Nano Crystal colloidal dispersions of drug substance are combined with water-
soluble GRAS (Generally Regarded As Safe) ingredients, filled into blisters, and lyophilized. 
The resultant wafers are remarkably robust, yet dissolve in very small quantities of water in 
seconds. This approach is especially attractive when working with highly potent or 
hazardous materials because it avoids manufacturing operations (e.g; granulation, blending, 
and tableting) that generate large quantities of aerosolized powder and present much higher 
risk of exposure. The freeze-drying approach also enables small quantities of drug to be 
converted into ODT dosage forms because manufacturing losses are negligible. 
 
 
 
Introduction 
Padmavathi College of Pharmacy and Research Institute  9 
 
C. Conventional technologies 
1. Freeze drying  
A process, in which water is sublimated from the product after freezing, is called 
freeze drying. Freeze-dried forms offer more rapid dissolution than other available solid 
products. The lyophilization process imparts glossy amorphous structure to the bulking agent 
and some times to the drug, thereby enhancing the dissolution characteristics of the 
formulation. However, the use of freeze drying is limited due to high cost of the equipment 
and processing. Other major disadvantages of the final dosage forms include lack of physical 
resistance in standard blister packs.  
A tablet that rapidly disintegrates in aqueous solution includes a partially collapsed 
matrix network that has been vacuum dried above the collapse temperature of the matrix. 
The matrix is partially dried below the equilibrium freezing point of the matrix. Vacuum 
drying the tablet above its collapse temperature instead of freeze drying below its collapse 
temperature provides a process for producing tablets with enhanced structural integrity, 
while rapidly disintegrating in normal amounts of saliva.  
 
2. Moulding  
Tablets produced by moulding are solid dispersions. Physical form of the drug in the 
tablets depends whether and to what extent, it dissolves in the molten carrier. The drug can 
exist as discrete particles or micro particles dispersed in the matrix. It can dissolve totally in 
the molten carrier to form solid solution or dissolve partially in the molten carrier and the 
remaining particles stay undissolved and dispersed in the matrix. Disintegration time, drug 
dissolution rate and mouth feel will depend on the type of dispersion or dissolution.    
Moulded tablets disintegrate more rapidly and offer improved taste because the 
dispersion matrix is, in general, made from water soluble sugars. Moulded tablets typically 
do not possess great mechanical strength. Erosion and breakage of the moulded tablet often 
occur during handling and opening of blister packs.  
Moulded tablets usually are prepared from soluble ingredients by compressing a 
powder mixture previously moistened with solvent (usually water or ethanol) into mould 
plates to form wetted mass (compression moulding). Recently moulded forms also have been 
prepared directly from the molten matrix in which the drug is dissolved or dispersed (heat 
moulding) or by evaporating the solvent from the suspension at standard pressure (no-
vacuum lyophilization).  
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3. Direct compression4-7  
It is the easiest way to manufacture tablets. Conventional equipment, commonly 
available excipients and a limited number of processing steps are involved in direct 
compression. Also high doses can be accommodated and final weight of tablet can easily 
exceed that of other production methods. Directly compressed tablet's disintegration and 
solubilization depends on single or combined action of disintegrates, water soluble excipients 
and effervescent agent. Disintegrate efficacy is strongly affected by tablet size and hardness. 
Large and hard tablets have disintegration time more than that usually required. As 
consequences, products with optimal disintegration properties often have medium to small 
size and /or high friability and low hardness. Breakage of tablet edges during handling and 
tablet rupture during the opening of blister alveolus, all result from insufficient physical 
resistance. 
Disintegrants have major role in the disintegration and dissolution process of mouth 
dissolving Tablets made by direct compression. To ensure a high disintegration rate, choice 
of suitable type and an optimal amount of disintegrant is important. Other formulation 
components such as water soluble excipients or effervescent agents can further enhance 
dissolution or disintegration properties. But main drawback of using effervescent excipients 
is their highly hygroscopic nature.  
The understanding of disintegrant properties and their effect on formulation has 
advanced during last few years, particularly regarding so called superdisintegrants. 
Disintegration efficiency is based on force equivalent concept, which is the combined 
measurement of swelling force development and amount of water absorption. Force 
equivalent expresses the capability of disintegrant to transform absorbed water into swelling 
force. The optimization of tablet disintegration was defined by means of disintegrant critical 
concentration. Below this concentration, the tablet disintegration time is inversely 
proportional to disintegrate concentration and above that disintegration time remains 
approximately constant or even increases.  
The simultaneous presence of disintegrate with a high swelling force called 
disintegrating agent and substances with low swelling force ( starch, cellulose and direct 
compression sugar) defined as, "swelling agent" was claimed to be a key factor for rapid 
disintegration of tablet, which also offers physical resistance.  
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4. Spray-drying  
Highly porous and fine powders can be produced by spray drying, as the processing 
solvent is evaporated rapidly during spray drying. Spray drying technique has been 
employed   to prepare fast dissolving tablets. They developed formulation by using mannitol 
as bulking agent, hydrolysed and non-hydrolysed gelatin as support matrix, sodium starch 
glycolate as disintegrant and acidic material (eg; citric acid) and/or alkali material (eg; 
NaHCO3) to enhance disintegration and dissolution. When immersed in an aqueous medium, 
the tablets compressed from spray-dried powder, disintegrated within 20 seconds.  
 
5. Sublimation  
Because of low porosity, compressed tablets composed of highly water-soluble 
excipients as tablet matrix material often do not dissolve rapidly in the water. Porous tablets 
that exhibit good mechanical strength and dissolve quickly have been developed. Inert solid 
ingredients (e.g.; urea, urethane, ammonium carbonate, camphor, naphthalene) were added to 
other tablet excipients and the blend was compressed into tablet. Removal of volatile 
material by sublimation generated a porous structure.  
A method of producing fast dissolving tablet using water as the pore forming material 
has been described by Makino. Compressed tablets containing mannitol and camphor have 
been prepared by sublimation technique. The tablets dissolve within 10-20 seconds and 
exhibit sufficient mechanical strength for practical use. Koizumi have developed a new 
method of preparing high porosity rapidly saliva soluble compressed tablets using mannitol 
with camphor, a subliming material. 
 
6. Mass-extrusion  
This technology involves softening the active blend using the solvent mixture of 
water soluble polyethylene glycol, using methanol and expulsion of softened mass through 
the extruder or syringe to get a cylinder of the product into even segments using heated blade 
to form tablets. The dried cylinder can also be used to coat granules of bitter tasting drugs 
and thereby masking their bitter taste. 
 
1.4. Taste masking technologies in Oral Pharmaceuticals 
Taste is one of the most important parameters governing patient compliance. 
Undesirable taste is one of several important formulation problems that are encountered with 
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certain drugs. Oral administration of bitter drugs with an acceptable degree of palatability is 
a key issue for health care providers, especially for pediatric patients. 
  Taste masking is defined as a perceived reduction of an undesirable taste that would 
otherwise exist. 
 
A. General taste masking practices in Oral Pharmaceuticals 
Various techniques available for masking bitter taste of drugs include taste masking 
with ingredients such as flavors, sweeteners, and amino acids; taste masking by polymer 
coating; taste masking by conventional granulation; taste masking with ion-exchange resins; 
taste masking by spray congealing with lipids; taste masking by formation of inclusion 
complexes with cyclodextrins; taste masking by the freeze-drying process; taste masking by 
making multiple emulsions; and taste masking with gelatin, gelatinized starch, liposomes, 
lecithins or lecithin-like substances, surfactants, salts, or polymeric membranes. 
 
1. Taste masking with flavors, sweeteners, and amino acids 
This technique is the foremost and the simplest approach for taste masking, 
especially in the case of pediatric formulations, chewable tablets, and liquid formulations. 
But this approach is not very successful for highly bitter and highly water soluble drugs. 
Artificial sweeteners and flavors are generally being used along with other taste-masking 
techniques to improve the efficiency of these techniques. The cooling effect of the taste 
masking agents also aids in reducing the bitterness. Menthol reduces the bitter taste, and low-
calorie formulations show beneficial effects. 
Aspartame is used as a prominent sweetener in providing bitterness reduction. A very 
small concentration (0.8%) is effective in reducing the bitterness of 25% acetaminophen. 
Starch, lactose, and mannitol have also exhibited taste-masking properties of caffeine. 
Artificial sweeteners such as neohesperidine dihydrochalcone and hesperidine 
dihydrochalcone 4’-β-D glucoside have the ability to mask bitterness and saltiness by virtue 
of their lingering sweetness. 
 
2. Taste masking with lipophilic vehicles 
Oils, surfactants, polyalcohols, and lipids effectively increase the viscosity in the 
mouth and coat the taste buds, and therefore they are potential taste masking agents. 
1. Guaifenesin Melt granulation Carnauba wax and magnesium aluminium silicate.  
2.  Cimetidine Granulation Glyceryl monostearate.  
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Lecithin and Lecithin-like Substances Formulations with a large excess of lecithin or 
lecithin-like substances are claimed to control bitter taste in pharmaceuticals. Magnesium 
aluminum silicate with soybean lecithin is used to mask the unpleasant taste of Ampicillin 
HCl. The drug is dissolved in or dispersed into an organic solvent such as chloroform. 
 
3. Taste masking by coating with hydrophilic vehicles 
This is the simplest and most feasible option to achieve taste masking. The coating 
acts as a physical barrier to the drug particles, thereby minimizing interaction between the 
drug and taste buds. Coating of chewable tablets provides excellent taste masking while still 
providing acceptable bioavailability. A specialized technique, i.e., micro emulsion 
technology, has been used for taste masking of powders, chewable tablets, and liquid 
suspensions. 
 
4. Carbohydrates (Cellulose) 
The taste of orally administered drugs can be masked by coating the drug with 
carbohydrates. Bitter solid drugs such as pinaverium bromide, a spasmolytic, has no bitter 
taste when formulated in an organoleptically acceptable manner by polymer coating with a 
mixture of cellulose or shellac and a second film forming polymer soluble at pH less than 5. 
Taste masking of ibuprofen has been successfully achieved by using the air-
suspension coating technique to form microcapsules, which comprise a pharmaceutical core 
of crystalline ibuprofen and a methacrylic acid copolymer (Eudragit) coating that provides 
chewable taste-masked characteristics. 
 
5. Taste masking by inclusion complexation  
In inclusion complex formation, the drug molecule fits into the cavity of a 
complexing agent, i.e., the host molecule, forming a stable complex. The complexing agent 
is capable of masking the bitter taste of drug by either decreasing its oral solubility on 
ingestion or decreasing the amount of drug particles exposed to taste buds, thereby reducing 
the perception of bitter taste. This method is most suitable only for low dose drugs. Vander 
waals forces are mainly involved in inclusion complexes. β-cyclodextrin is the most widely 
used complexing agent for inclusion type complexes. It is a sweet, nontoxic, cyclic 
oligosaccharide obtained from starch.  
The strong bitter taste of carbetapentane citrate syrup was reduced to approximately 
50% by preparing a 1:1 complex with cyclodextrin. Palatable ibuprofen solutions are 
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prepared by forming a 1:11 to 1:15 inclusion complex with ibuprofen and hydroxypropyl β-
cyclodextrin, respectively. The complex masked the bitter component but created a sore taste 
that was masked by sweeteners. 
 
6. Taste masking by Ion-exchange resins (IERs)6,8 
Ion-exchange resins (IERs) are high molecular weight polymers with cationic and 
anionic functional groups. The most frequently employed polymeric network is a copolymer 
of styrene and divinylbezene. Ion-exchange resins are used in drug formulations to stabilize 
the sensitive components, sustain release of the drug, disintegrate tablets, and mask taste. 
Drug can be bound to the resin by either repeated exposure of the resin to the drug in a 
chromate graphic column or by prolonged contact of resin with the drug solution.  
Drugs are attached to the oppositely charged resin substrate, forming insoluble 
adsorbates or resonate through weak ionic bonding so that dissociation of the drug-resin 
complex does not occur under the salivary pH conditions. This suitably masks the unpleasant 
taste and odor of drugs. 
Drug release from the resin depends on the properties of the resin and the ionic 
environment within the gastrointestinal tract (GIT). Drug molecules attached to the resin are 
released by exchanging with appropriately charged ions in the GIT, followed by diffusion of 
free drug molecule out of the resins. 
Ion exchange resins can be classified into four major groups:  
• Strong acid cation-exchange resin. 
• Weak acid cation-exchange resin. 
• Strong base anion-exchange resin. 
• Weak base anion-exchange resin. 
 
B. Miscellaneous taste-masking approaches 
1. By effervescent agent  
Effervescent agents have been shown to be useful and advantageous for oral 
administration of drugs and have also been employed for use as taste-masking agents for 
dosage forms that are not dissolved in water prior to administration. A chewing gum 
composition of bitter medicament(s) was formulated to supply the medicament(s) to the oral 
cavity for local application or for buccal absorption. It comprises a chewing gum base, an 
orally administrable medicament, a taste masking generator of carbon dioxide, and 
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optionally a taste bud desensitizing composition (e.g; oral anesthetics such as benzocaine and 
spilanthol) and other non active materials, such as sweeteners, flavoring components, and 
fillers. Recently, effervescent tablets of fentanyl and prochlorperazine were developed to 
supply these drugs to the oral cavity for buccal, sublingual, and gingival absorption. The 
formulations contain the drugs in combination with effervescent agent(s) to promote their 
absorption in the oral cavity and to mask their bitter taste.  
 
2. Salt preparation 
Salt preparation is one of the classical approaches to mask the bitter taste of drug by 
either decreasing solubility or by increasing hydrophobicity and thereby reducing contact of 
bitter drugs with taste buds. This approach differs others to modify the chemical composition 
of the drug substance itself, so as to render it less soluble in saliva and thereby less 
stimulating to the taste buds, or to obtain a tasteless or less bitter form. Adding alkaline metal 
bicarbonate such as sodium bicarbonate masks the unpleasant taste of water-soluble 
ibuprofen salts in aqueous solution. The bitter taste of caffeine may be masked by 
formulating it as a carbonated oral solid preparation using sodium bicarbonate, ascorbic acid, 
citric acid, and tartaric acid. Magnesium aspirin tablets are rendered tasteless by preparing 
magnesium salts of aspirin. 
 
3. Solid dispersion systems 
Solid dispersions can be defined as the dispersion of one or more active ingredients in 
an inert solid carrier. Solid dispersion of drug with the help of polymers, sugar, or other 
suitable agents, is very useful for taste masking. The bitter taste of dimenhydrinate can be 
masked by preparing the solid dispersion of the drug with polyvinyl acetate phthalate. 
 
4. Group alteration and prodrug approach 
The alkyloxyalkyl carbonates of the Clarithromycin 2’ position have remarkably 
alleviated bitterness and improved bioavailability when administered orally. 
Tasteless/ bitter less prodrugs of opioid analgesics and antagonists were formulated 
for improved buccal delivery. Tasteless prodrugs of Nalbuphine HCl, Naltrexone, Naloxone, 
Oxymorphone HCl, Butorphanonol, and Levallorphan were synthesized for buccal 
administration to improve bioavailability relative to that of oral dosing without the 
characteristic bitter taste. In rats, the prodrugs demonstrated up to 90% bioavailability. It was 
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concluded that when administered as prodrugs, bioavailability improved without visible 
adverse effects. 
 
5. Freeze drying process 
This method is used to develop fast-dissolving oral technologies such as Zydis and 
Lyoc technology. Zydis is a tablet-shaped dosage form that spontaneously disintegrates in 
the mouth in seconds. This is due to the high porosity produced by the freeze drying process. 
The Zydis process requires the active ingredient to be dissolved or suspended in an 
aqueous solution of water-soluble structure formers. The resultant mixture is then poured 
into the preformed blister pockets of a laminate film and freeze dried. The two most 
commonly used structural excipients are gelatin and mannitol, although other suitable 
excipients can be used (e.g; starches, gums, etc.). This process is ideally suited to low 
solubility drugs as these are more readily freeze dried. 
 
6. Wet spherical agglomeration (WSA) technique and continuous 
multipurpose melt (CMT) technology 
A novel micro encapsulation process combined with the wet spherical agglomeration 
(WSA) technique was used to mask the bitter taste of Enoxacin. 
1.5. Mechanism of tablet disintegration and water absorption   
When mouth dissolving tablets placed in the mouth, upon contact with saliva the 
tablets disintegrates or dissolve instantaneously. There are four mechanisms involved in the 
tablet disintegration mechanisms  
a) Swelling 
b) Wicking (capillary) 
c) Deformation 
d) Chemical reaction (acid base reaction) 
 
a. Swelling 
Not all disintegrates swell in contact with water swelling is believed to be a 
mechanism in which; certain disintegrating agents (like starch) impart their disintegrating 
effect. By swelling in contact with water, the adhesiveness of other ingredients in a tablet is 
overcome causing the tablet to disintegrate.  
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b. Wicking (porosity and capillary action) 
Effective disintegratnts that do not swell are believed to impart their disintegrating 
action through porosity and capillary action. Tablets porosity provides way for the 
penetration of fluid into tablets. The disintegrants particles (with cohesiveness and 
compressibility) themselves act to enhance porosity and provide these capillaries into the 
tablets. Liquid is drawn up or wicked into these ways by capillary action and rupture the 
inter-particulate bonds causing the tablet to break into small parts. 
 
c. Deformation 
Starch grains are generally thought to be “elastic” in nature that is the grains that are 
deformed under pressure will return to their original shape when that pressure is removed. 
But, with the compression forces involved in tabletting, these grains are permanently 
deformed and are said to be “energy rich” with these energy being released upon exposure to 
water, that is the ability for starch to swell is higher in “energy rich” starch grains than in 
starch grains that have not been deformed under pressure. It is belived that no single 
mechanism is responsible for the action of most disintegrants. But rather, it is more likely the 
results of inter-relationships between these major mechanisms. 
 
 E. Chemical reaction (acid base reaction) 
Disintegration of tablet is inclusion of citric acid and tartaric acid along with the 
sodium bicarbonate, sodium carbonate, potassium carbonate; these react in contact with 
water to liberate carbon dioxide that disrupts the tablet.   
 
F. Factors affecting action of disintegrants 
9 Percentage of disintegrants presents in the tablets 
9 Type of substances present in the tablet 
9 Combination of  disintegrants 
9 Presence of surfactants 
9 Hardness of the tablet 
9 Nature of drug substances. 
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Table No:2 Marketed fast disintegrating tablets9 
 
Name of the Product Active Ingredients 
Imodium Lingual Imodium 
Pepcidin Rapitab Quick releasing antiulcer preparation of pepcid 
Mosid – MT Mouth melt tablet of Mosapride citrate. 
Calritin Reditabs Immediate Dissolving formulation of Calritin 
Nimulid – MD Nimesulide 
Zyrof Meltab Rofecoxib 
Claritin Reditab Micronized loratadine 
Feldene Melt Piroxicam (10 or 20 mg), 
Maxalt-MLT Rizatriptan (5 or 10 mg), peppermint flavor 
Pepcid RPD Famotidine (20 or 40 mg), 
Zyprexa Zydis Olanzapine (5, 10, 15 or 20 mg), 
Zofran ODT Ondansetron (4 or 8 mg), strawberry flavor 
Remeron Soltab Mirtazepine (15, 30, or 45 mg), orange flavor 
Tempra FirstTabs 
Acetaminophen (80 or 160 mg), (currently available 
in Canada) 
NuLev Hyoscyamine sulfate (0.125 mg), mint flavoring 
Zomig ZMT Zolmitriptan (2.5 mg), orange flavor 
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2. LITERATURE REVIEW 
 
Yoshio et.al., (2008) evaluated the effect of lubricants on the characteristics of orally 
disintegrating (OD) tablets manufactured using the phase transition of sugar alcohol. OD tablets 
were produced by directly compressing a mixture containing lactose–xylitol granules, 
disintegrant, glidant and lubricant, and subsequent heating. The effect of the type of lubricant on 
the tablet characteristics was evaluated using magnesium stearate (mg-st), sodium stearyl 
fumarate (SSF), and talc as lubricants. the hardness of the tablets increased to ca. 6 kp as a result 
of heating, regardless of the kind of lubricant. the oral disintegration time of the tablets 
containing mg-st or ssf increased with an increase in the hardness. In contrast, the oral 
disintegration time of the tablets containing talc was not changed despite of an increase in 
hardness. The water absorption rate of the tablets containing talc was much faster than that of 
the tablets containing other lubricants. The water absorption rate of the tablets containing talc 
was also increased by heating.12  
 
Yoshio et.al., (2008) evaluated the effect of preparation method on the properties of orally 
disintegrating (OD) tablets, OD tablets were prepared by compressing a mixture of high melting 
point sugar alcohol (HMP-SA) and low melting point sugar alcohol (LMP-SA) and subsequent 
heating. In the direct compression method (DCM) where the LMP-SA was added as a powder, 
both hardness and disintegration time were increased by decreasing the particle size of the LMP-
SA. In the wet granule compression method (WGCM), where the LMP-SA was added as an 
aqueous binder solution, the tablets became harder with less heating compared to tablets 
prepared by DCM. Using 1% xylitol as the LMP-SA provided tablets with sufficient hardness 
when prepared by WGCM, as opposed to DCM where 5% xylitol was necessary to prepare 
tablets with similar hardness. These results suggest that uniformly distributed LMP-SA on the 
surface of HMP-SA particles in WGCM might diffuse more easily during the heating process 
compared to mechanically mixed LMP-SA in DCM, resulting in an increase in tablet hardness 
even with a short heating time and low content of LMP-SA. In addition, disintegration and 
hardness stability of the tablets were affected by the LMP-SA content when prepared by 
WGCM, suggesting that the LMP-SA content should be regulated to assure the stability of OD 
tablet characteristics13. 
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Jianchen et.al., (2008) evaluated the potential of microspheres for taste masking when 
incorporated into orally disintegrating tablets. The microspheres were produced by spray drying 
a mixture of the model compound (famotidine) with taste masking material. The spray process 
was optimized using a central composite design for two variables to obtain microspheres with 
desirable characteristics. Then the microspheres were mixed with other excipients to form orally 
disintegrating tablets. The optimal spray-drying process parameters were 34 mg/ml for solid 
concentration and 7 ml/min for feed rate. The drug encapsulation efficiency of the spray-dried 
microspheres ranges from of 37.59 to 61.56%, with a mean diameter of less than 10m size and 
low moisture content (less than 4%). Results from an evaluation by a panel of six human 
volunteers demonstrated that the orally disintegrating tablets with taste masking microspheres 
improved the taste significantly. Furthermore, an in vivo study in rats showed that the 
microspheres neither decrease the bioavailability nor retard the release of famotidine 
significantly. In conclusion, spray-dried microspheres can effectively mask the bitter taste of the 
active pharmaceutical ingredients in combination with the orally disintegrating tablets14. 
 
Riikka et.al., (2008) have studied, the dissolution rate of a poorly soluble drug, perphenazine 
(PPZ) was improved by a solid dispersion technique to permit its usage in intraoral 
formulations. Dissolution of PPZ (4 mg) in a small liquid volume (3 ml, pH 6.8) within one 
minute was set as the objective. PVP K30 and PEG 8000 were selected for carriers according to 
the solubility parameter approach and their 5/1, 1/5 and 1/20 mixtures with PPZ (PPZ/polymer 
w/w) were prepared by freeze-drying from 0.1 N HCl solutions. The dissolution rate of PPZ was 
improved with all drug/polymer mixture ratios compared to crystalline or micronized PPZ. A 
major dissolution rate improvement was seen with 1/5 PPZ/PEG formulation, i.e. PPZ was 
dissolved completely within one minute. SAXS, DSC and XRPD measurements indicated that 
solid solutions of amorphous PPZ in amorphous PVP or in partly amorphous PEG were formed. 
DSC and FTIR studies suggested that PPZ dihydrochloride salt was formed and hydrogen 
bonding was occurred between PPZ and the polymers. It was concluded that molecular mixing 
together with salt formation promoted the dissolution of PPZ, especially in the case of the 1/5 
PPZ/PEG dispersion, making it a promising candidate for use in intraoral formulations15. 
 
Adam et.al., (2007) formulated the fast dispersible/slow releasing ibuprofen tablets. To prevent 
bitter taste and side effects of the drug, the drug was associated with Phospholipon 80H, a 
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saturated lecithin, by wet granulation. The granules were then coated using different film 
forming agents (Kollicoat SR 30, Amprac 01, Kollidon 90F, Eudragit RD 100) obtaining four 
lots 1–4. Coated granules were then formulated with a sweetener (Aspartame), a mannitol-based 
diluent (Pearlitol SD 200) and Kollidon CL (1-4K) or Explotab (1-4E) were added as 
superdisintegrants and compacted under low compression force. By an appropriate combination 
of excipients it was thus possible to obtain orally disintegrating tablets and a delayed release of 
ibuprofen using simple and conventional techniques16. 
 
Seong et.al., (2007) have developed a complex formation between drugs and ion-exchange 
resins was investigated and the effects of coating by various aqueous polymeric dispersionson 
the complexes were evaluated for developing new sustained-release fast-disintegrating tablets 
(FDTs). Complexes of ion-exchange resin and dextromethorphan, a model drug, were prepared 
using different particle sizes of the resins. As the particle size of resins increased, the drug 
loading and release rate decreased due to the reduced effective diffusion coefficient and surface 
area. When the drug release profiles were applied into Boyd model and Higuchi equation, the 
linear relationship was observed, indicating that the diffusion within the resin matrix is the rate-
controlling step17. 
 
Devi et.al., (2006) were prepared oro dispersable flucanozole tablets. Oro dispersable tablets of 
flucanozole were prepared with two different volatilizable compound viz, ammonium 
chloride,and camphor. Eight formulations were prepared with varying concentration of 
volatalizable substances by wet granulation. These tablets were evaluated for their friability, 
weight variation, hardness, disintegration time, and pH of the solution after dispersion, the best 
formulation were choosen and compared with marketed conventional tablets.These oro 
dispersable fluconazole tablets can be focused for treating of oral fungal infections particularly 
in premature infants, geriatrics bed ridden patients, patients receiving immuno suppressive 
therapy and AIDS patients18. 
 
Jinichi et.al., (2006) have developed a rapidly disintegration tablet in the oral cavity was 
prepared using a glycine as a disintegrant. Effect of disintegrant on the disintegration behavior 
of the tablet in the oral cavity was evaluated. It was suggested that the tablet formulation 
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containing carboxymethylcellulose (NS-300) and glycine was highly applicable to water-
insoluble drug, such as ethenzamide19. 
 
Chaudari et.al., (2006) were prepared rizatriptan benzoate oral disintegrating tablets.Taste 
masked by using indion214 resin.They conducted the drug release studies at mouth salivary pH 
and at gastric pH. They obtain complete drug release at gastric pH20. 
 
Shishu et.al., (2006) were prepared compressed tablets of diazepam which disintegrate in the 
oral cavity were prepared using microcrystalline cellulose as directly compressible filler and 
sodium starch glycolate as super disintegrants. The taste is masked by preparing microspheres 
using amino alkyl methyl acrylate copolymer (Eudragit E-100) by solvent evoparation method. 
Taste evolutions of these microspheres were done by both spectrophotometric taste evolution 
technique and panel testing21. 
 
Prajapati et.al., (2006) were dispersible tablets of an insoluble drug nimesulide was prepared 
by wet granulation method. Using 0.5%w/v aqueous PVP K-30 as binder. Plkanatago ovata used 
as a superdisintegrating agent and compared with sodium starch glycolate, cross carmellose 
sodium Swelling index was investigated with an aim to evaluate super disintegrants from 
mucilage of plantago ovata and and compared with sodium starch glycolate, cross carmellose 
sodium. They showed highest swelling index indicating the required properties of 
disintegrants22. 
 
Masaaki et.al., (2005) were studied the factors affecting the characteristics of rapidly 
disintegrating tablets containing an amorphous ingredient prepared by crystalline transition 
method (CTM) under various storage conditions. Effect of storage   conditions and formulating 
ratio of amorphous sucrose on the characteristic changes (tensile strength, porosity, and 
disintegration time) of the rapidly disintegrating tablets was studied. The storage conditions of 
different temperature and humidity affected the rate of crystalline transition and the increase in 
the tablet tensile strength. The faster crystalline transition resulted in a faster rate of increase in 
the tablet tensile strength. Regarding the effect of the formulating ratio of amorphous sucrose.  
In the case of 20–100%. Hence, the higher formulating ratio of amorphous sucrose provided the 
longer disintegration time in the mouth23.  
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Takao et.al., (2005) have  formulated a novel fast-disintegrating tablets. Saccharides can be 
divided into high- and low-compressibility categories, and an appropriate material for fast-
disintegrating tablets was created by taking advantage of this fact. To improve the 
compressibility of low-compressibility saccharides, particle modification was conducted by 
coating and granulating a low-compressibility saccharide with a high one to enable the 
production of a fast-disintegrating tablet24.  
 
Mesut et.al., (2005) have prepared novel capsule-based fast disintegrating dosage forms for the 
oral cavity (Fastcaps). First, cast films were prepared from various additive-containing gelatin 
solutions and evaluated with respect to disintegration time and mechanical properties in order to 
identify suitable formulations for the capsule preparation. The disintegration time of films 
decreased with decreasing bloom strength and could be further decreased by the addition of 
sugars or PEGs. Fast disintegrating capsules were successfully prepared by a dipping process, 
whereby parameters such as the viscosity and temperature of the dipping solution and the 
dipping velocity of the steel pins were optimized. The required viscosity range of the dipping 
solution for Fastcap manufacturing was 500–600 cP. The addition of the hydrophilic additives 
(xylitol, sorbitol or PEG 1500) did not significantly affect the viscosity and gelation temperature 
of the dipping solution. The in vitro disintegration of Fastcaps (30–45 s) was twice as rapid as 
the one of regular hard gelatin capsules. In vivo, Fastcaps disintegrated rapidly (9–13 s). Lactose 
and/or microcrystalline cellulose were suitable fillers for Fastcaps. The mechanical properties of 
Fastcaps were similar to commercially available gelatin capsules, which assures good  
processability and handling25. 
 
Mishra et.al., (2005) were prepared rapidly disintegrating oral tablets of valdecoxib. 
Valdecoxib is a non-steroidal anti inflammatory property. Valdecoxib has poor aqueous 
solubility results in variable in dissolution rate. In this present work prepare fast disintegrating 
tablets using various super disintegrants following direct compreesion. All formulation showed 
disintegration time less than 60 sec. Along with rapid invitro dissolution. It was concluded that 
the fast disintegrateing tablets of the poorly soluble drugs can be made by direct compression 
technique using selective super disintegrants showing enhanced dissolution. And hence better 
compleance and effective therapy26. 
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Chaudari et.al., (2005) were prepared fast dissolving tablets of famotidine. It is a H2 receptor 
antagonist. It inhibits acid production by reversibly competing with histamine for binding to H2 
receptor on the baso lateral membrane of perietal cells. It is commonly used drug but the major 
disadvantage is its bitterness and low bioavalibilty. The bitter taste of famotidine was masked by 
preparing the solid dispersion using eudragit E-100. solid dispersion is prepared by solvent 
evaporation method. Taste evaluation is done by humanvolunteers using time intensity 
method27. 
 
Amin et.al., (2005) were prepared fast disintegrating dosage form of ofloxacin and 
metronidazole benzoate. Ofloxacin is a second generation floroquinolone, is a bitter anti 
bacterial. Taste is masked of ofloxacin by using cationic exchange resin(indion 204), In this 
work ion exchange resin Indian 414 used as super disintegrants. Comparative study with 
existing super disintegrants was carried out28. 
 
Dandagi et.al., (2005) were prepared rapidly disintegrating domperidone tablets. In this work 
rapidly disintegrating tablets were prepared by two methods  1) sodium starch glycolate and 
treated agar used as super disintegrants in mass extrusion technique.2) Treated agar methodall 
formulation show good palatable mouth feel, and rapid disintegrating time29. 
 
Vijaya et.al., (2005) were prepared disintegrating oral tablets of meloxicam. Meloxicam is an 
effective and selective cyclo oxygenase cox-2 inhibitor with anti inflammatory and analgesic 
properties. The poor aqueous solubility of the drug leads to variable dissolution rates. In this 
study an attempt has been made to prepare fast disintegrating tablets of meloxicam in the oral 
cavity with enhanced dissolution rate. The tablets were prepared with three super disintegrants, 
sodium starch glycolate, ac-di-sol, and low molecular weight hydroxy propyl methyl cellulose. 
The blend was examined for angle of repose, bulk density, tapped density, compressibility 
index, and hautionar ratio30. 
 
Kaushik et.al., (2004) were prepared olanzapine tablets which dissolves rapidly in mouth, there 
fore needing not be swallowed. Mouth dissolving tablets of olanzapine were prepared by 
effervescent formulation approach. The effervescent Excipient system not only rapid dissolution 
of tablets in the oral cavity also masks the slight bitter taste of medicament. Sodium bi 
carbonate, and citric acid were used as effervescent agents. Sodium bi carbonate and citric acid 
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in the formulation gave a soothing fizz, excellent mouth feel, good palatability, and quick 
dissolution profile31. 
 
Kucheka et.al., (2004) were developed mouth dissolving tablets of salbutamol sulphate, It is a 
selective b2 receptor agonist widely used as bronchodilator. Formulation was designed by 
factorial design technique.Sodium starch glycolate, crosscarmellose sodium, and treated ager 
werte used as super disintegrants. while micro crystalline cellulose was used as diluent. Direct 
compression technique was used as it requires conventional tablet machienary and thus 
economical process. Formulation containing sodium starch glycolate, along with other super 
disintegrants, showed rapid in vitro band invivo dispersion time, as compared to other 
formulation32. 
 
Mahajan et.al., (2004) were prepared mouth dissolve tablets of sumatriptan succinate. Prepared 
the tablets by using disintegrants sodium starch glycolate, carboxy methyl cellulose, and treated 
agar by direct compression method. The prepared tablets were evaluated for thickness, 
uniformity of weight, content uniformity, hardness, tensile strength, porosity, wetting time, 
water absorption ratio, in vitro and in vivo disintegrating time33. 
 
Beatrice et.al., (2002) have formulated the design carbamazepine fast-release tablets, prepared 
by melt granulation technique, involving the use of melt granulation process in high shear mixer 
for the production of tablets. In particular, the granules containing CBZ were prepared using 
polyethylene glycol (PEG) 4000 as a melting binder and lactose monohydrate as hydrophilic 
filler. The potential of the intragranular addition of crospovidone as a dissolution enhancer and a 
disintegrant agent was also evaluated. After the analysis of their solid state performed by means 
of X-ray powder diffraction (XRD) and differential scanning calorimetry (DSC), However, the 
difficult disintegration and bad dissolution performance of the tablets not containing 
intragranular crospovidone highlight the necessity of this disintegrant in the granulating mixture. 
Moreover, the extragranular addition of a small amount of crospovidone gave rise to a further 
amelioration of the disintegration and dissolution performances34. 
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3. AIM AND OBJECTIVE 
 
Fast disintegrating tablets are becoming popular as one of the user friendly dosage forms. 
Our purpose is to develop an original composition of fast disintegrating tablet by using 
conventional tablet manufacturing process. The basic approach used in the development of fast 
disintegrating tablets is the use of superdisintegrants. Cros Carmellose Sodium, Sodium Starch 
Glycolate, and Crospovidone, low-subsititued Hydroxyl Propyl Cellulose were used in the 
present study. Before that, bitter taste of Naproxen sodium was masked by using sweetner. 
This study was under taken with the aim to formulate and evaluate taste masked fast 
disintegrating tablets to avert the problems of swallowing and to provide rapid on set of action. 
The drug chosen for present study is Naproxen sodium. 
The present work is to study the effect of various superdisintegrants on drug (Naproxen 
sodium) by direct compression methods. In the present study tablets will be prepared at 
approximately equal hardness.  
The dissolution profiles of drug will be compared for tablets containing different 
superdisintegrants then to compare the effect of superdisintegrants on the in vitro dissolution 
and in vitro disintegration in pH 6.8 Phosphate buffer as dissolution medium. 
Plan of Work 
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4. PLAN OF WORK 
 
¾ To prepare fast disintegrating tablets of Naproxen sodium using different super 
disintegrates. 
¾ To select the method of taste masking. 
¾ To select the formulation composition.  
¾ To test all physical evaluation parameters.  
¾ To construct the calibration curve for Naproxen sodium. 
¾ To study the drug dissolution profile. 
¾ To study the water absorption ratio.  
¾ To study the determine disintegration time.  
¾ To select the best formulation based on the above studies. 
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5. DRUG PROFILE 
 
Non proprietary name:   Naproxen sodium        
Chemical name           :    (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic sodium salt  
Molecular formula      :    C14H13NaO3 
Molecular weight        :     252.24 g/mol 
 
  
PHYSICOCHEMICAL PROFILE 
Description       :    An odorless crystalline powder, white to creamy in color.  
Melting point    :    250-251 ºC  
Solubility          :    It is soluble in methanol and water. 
  
PHARMACODYNAMICS 
The mechanism of action of Naproxen, like that of other NSAIDs, is believed to be 
associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have 
been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes 
prostaglandins necessary for normal gastrointestinal and renal function. The inducible 
cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of 
COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of 
COX-2 provides anti-inflammatory activity.  
 
PHARMACOKINETICS 
Although naproxen itself is well absorbed, the sodium salt form is more rapidly absorbed 
resulting in higher peak plasma levels for a given dose. After oral administration, plasma levels 
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of naproxen are detected within 30 minutes of dosing, with peak plasma levels occurring 
approximately 5 hours after dosing.  
 ABSORPTION 
Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo 
bioavailability of 95%.   Based on the pharmacokinetic profile. 
 
DISTRIBUTION 
Naproxen has a volume of distribution of 0.16 L/kg. At therapeutic levels, naproxen is 
greater than 99% albumin-bound. At doses of naproxen greater than 500 mg/day, there is a less 
than proportional increase in plasma levels due to an increase in clearance caused by saturation 
of plasma protein binding at higher doses.  
 
METABOLISM 
Naproxen is extensively metabolized to 6-0-desmethyl Naproxen and both parent and 
metabolites do not induce metabolizing enzymes. 
 
ELIMINATION 
The elimination half-life of naproxen is approximately 15 hours. Steady state conditions 
are attained after 2-3 doses of Tablets. Most of the drug is excreted in the urine, primarily as 
unchanged naproxen (less than 1%), 6-0-desmethyl naproxen (less than 1%) and their 
glucuronide or other conjugates (66-92%). A small amount (< 5%) of the drug is excreted in the 
feces. The rate of excretion has been found to coincide closely with the rate of clearance from 
the plasma. In patients with renal failure, metabolites may accumulate. 
 
USES: Naproxen sodium is used to relieve mild to moderate pain from various conditions (e.g; 
tendonitis, menstrual cramps). It also reduces pain, swelling, and joint stiffness caused by 
arthritis, bursitis, and gout. Reducing these symptoms helps you do more of your normal daily 
activities. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID). 
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Table No:3 Dosage form and dose 
Route Dosage forms 
 
Strength 
Oral Tablets, 220 mg 
 Tablets 275 mg 
 Tablets 550 mg 
 Naproxen sodium 
controlled-release 
550 mg/day 
 
DRUG INTERACTIONS 
This drug should not be used with the following medications because very serious 
interactions may occur: high doses of aspirin and related drugs (salicylates), cidofovir, other 
NSAIDs (e.g; ketorolac).  
Before using this medication, especially of: anti-platelet drugs (e.g;  cilostazol, 
clopidogrel), oral bisphosphonates (e.g; alendronate), "blood thinners" (e.g; enoxaparin, heparin, 
warfarin), corticosteroids (e.g; prednisone), cyclosporine, desmopressin, digoxin, high blood 
pressure drugs (including ACE inhibitors such as captopril, angiotensin receptor blockers such 
as losartan, and beta-blockers such as metoprolol), lithium, methotrexate, pemetrexed, 
probenecid, SSRI antidepressants (e.g; fluoxetine, sertraline), "water pills" (diuretics such as 
furosemide, hydrochlorothiazide, triamterene). Check all prescription and nonprescription 
medicine labels carefully for other pain/fever drugs (NSAIDs such as aspirin, celecoxib, 
ibuprofen). These drugs are similar to this medication, so taking one of these drugs while also 
taking this medication may increase your risk of side effects.  
 
The possible side effects of non-steroidal anti inflammatory drugs (NSAIDS) 
¾ Stomach pain, Gas  
¾ Constipation, Heartburn 
¾ Diarrhea, Nausea. 
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6. EXCIPIENT PROFILE 
 
       6.1 SODIUM STARCH GLYCOLATE 
Nonproprietary Names 
 
 
:
BP: Sodium starch glycollate 
PhEur: Carboxymethylamylum natricum 
USPNF: Sodium starch glycolate 
Synonyms 
 
: Carboxymethyl starch, sodium salt; Explosol; 
Explotab; Glycolys; Primojel; starch 
carboxymethyl ether, sodium salt. 
Chemical Name and CAS 
Registry Number 
: Sodium carboxymethyl starch [9063-38-1] 
 
 Structural Formula 
 
:
 
 Functional Category : Tablet and capsule disintegrant. 
Applications Pharmaceutical
Formulation or Technology 
 
 
: Sodium starch glycolate is widely used in oral 
pharmaceuticals as a disintegrant in capsule 
and tablet formulations. It is commonly used in 
tablets prepared by either direct-compression 
or wet-granulation processes. The usual 
concentration employed in a formulation is 
between 2% and 8%. Although the 
effectiveness of many disintegrants is affected 
by the presence of hydrophobic excipients 
such as lubricants, the disintegrant efficiency 
of sodium starch glycolate is unimpaired. 
Increasing the tablet compression pressure also 
appears to have no effect on disintegration 
time 
Excipient Profile 
Padmavathi College of Pharmacy and Research Institute   32 
 
Nonproprietary Names 
 
: BP: Crospovidone PhEur: Crospovidonum  
USPNF: Crospovidone 
Synonyms 
 
: Crosslinked povidone; E1202; Kollidon CL-
M; Polyplasdone XL; Polyplasdone XL-10; 
polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-
pyrrolidinone homopolymer. 
Chemical Name and CAS 
Registry Number 
: 1-Ethenyl-2-pyrrolidinone homopolymer  
[9003-398] 
 Empirical Formula and 
Molecular Weight 
: (C6H9NO)n   
The USPNF 23 describes crospovidone as a 
water-insoluble synthetic crosslinked 
homopolymer of  
N-vinyl-2-pyrrolidinone.  
Structural Formula : 
 
 Stability and Storage 
Conditions 
 
: Tablets prepared with sodium starch glycolate 
have good storage properties. Sodium starch 
glycolate is stable and should be stored in a 
well-closed container in order to protect it 
from wide variations of humidity and 
temperature, which may cause caking. 
 Safety 
 
 
 
 
6.2 CROSPOVIDONE 
 
: Sodium starch glycolate is widely used in oral 
pharmaceutical formulations and is generally 
regarded as a nontoxic and nonirritant material. 
However, oral ingestion of large quantities 
may be harmful. 
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Functional Category : Tablet disintegrant. 
Applications in 
Pharmaceutical 
Formulation or 
Technology 
: Crospovidone is a water-insoluble tablet 
disintegrant and dissolution agent used at 2–
5% concentration in tablets prepared by direct-
compression or wet- and dry-granulation 
methods. 
Description 
 
: Crospovidone is a white to creamy-white, 
finely divided, free-flowing, practically 
tasteless, odorless or nearly odorless, 
hygroscopic powder. 
Stability and Storage 
Conditions 
: Since crospovidone is hygroscopic, it should 
be stored in an airtight container in a cool, dry 
place. 
Safety : Crospovidone is used in oral pharmaceutical 
formulations and is generally regarded as a  
nontoxic and nonirritant material.  
 
      6.3 CROSCARMELLOSE SODIUM 
Nonproprietary 
Names 
: BP: Croscarmellose sodium 
PhEur: Carmellosum natricum conexum 
 USPNF: Croscarmellose sodium 
Synonyms 
 
: Ac-Di-Sol; crosslinked carboxymethylcellulose 
sodium; Explocel; modified cellulose gum; 
Nymcel ZSX; Pharmacel XL; Primellose; 
Solutab; Vivasol. 
Chemical Name and  : Cellulose, carboxymethyl ether, sodium salt,  
 Empirical Formula 
and Molecular Weight 
 
: Croscarmellose sodium is a crosslinked polymer 
of carboxymethylcellulose sodium. Typical 
molecular weight is 90 000–700 000. 
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Structural Formula 
 
: 
 
Functional Category : Tablet and capsule disintegrant 
Applications  
 
: Croscarmellose sodium is used in oral 
pharmaceutical formulations as a disintegrant 
for capsules, tablets, and granules. In tablet 
formulations, croscarmellose sodium may be 
used in both direct-compression and wet-
granulation processes.  
Description : Croscarmellose sodium occurs as an odorless, 
white or grayish-white powder 
Stability and Storage 
Conditions 
 
: Croscarmellose sodium is a stable though 
hygroscopic material. A model tablet 
formulation prepared by direct compression, 
with croscarmellose sodium as a disintegrant, 
showed no significant difference in drug 
dissolution after storage at 30°C for 14 months. 
Croscarmellose sodium should be stored in a 
well-closed container in a cool, dry place. 
 
6.4 LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE  
Nonproprietary Names : JP: Low-substituted hydroxypropylcellulose 
USPNF: Low-substituted hydroxypropyl cellulose 
 Synonyms : Hyprolose, low-substituted; L-HPC. 
Chemical Name and Registry 
Number 
: Cellulose, 2-hydroxypropyl ether (low-substituted). 
 Empirical Formula  : Hydroxypropoxy groups (—OCH2CHOHCH3).  
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Structural Formula : 
 
 Description : Low-substituted hydroxypropyl cellulose occurs as 
a white to yellowish white powder or granules. It is 
odorless or has a slight, characteristic odor, and it is 
tasteless. 
Functional Category : Tablet and capsule disintegrant; tablet binder 
Applications  in 
Pharmaceutical Formulation 
or Technology 
: Low-substituted hydroxypropyl cellulose is widely 
used in oral solid-dosage forms. It is primarily used 
in tableting as a disintegrant, and as a binder in wet 
granulation.  
 Stability and Storage 
Conditions 
 
: Low-substituted hydroxypropyl cellulose is a stable, 
though hygroscopic, material. The powder should 
be stored in a well-closed container. 
 Safety : Low-substituted hydroxypropyl cellulose is 
generally regarded as a nontoxic and nonirritant 
material.  
 
6.5 ASPARTAME 
Nonproprietary Names :  BP: Aspartame 
 PhEur: Aspartamum 
 USPNF: Aspartame 
 Synonyms : 3-Amino-N-(aì-
carboxyphenethyl)succinamic acid N-methyl 
ester;3-amino-(aìmethoxycarbonylphenethyl) 
succinamic acid; APM; aspartyl phenylamine 
methyl ester; 
Chemical Name and CAS Registry 
Number 
: N-aò-L-Aspartyl-L-phenylalanine 1-methyl 
ester [22839-47-0] 
Empirical Formula and Molecular 
Weight 
: C14H18N2O5       294.31 
Excipient Profile 
Padmavathi College of Pharmacy and Research Institute   36 
 
Structural Formula : 
 
Functional Category : Sweetening agent 
 Description : Aspartame occurs as an off white, almost 
odorless crystalline powder with an intensely 
sweet taste. 
Applications in Pharmaceutical 
Formulation or Technology 
: Aspartame is used as an intense sweetening 
agent in beverage products, food products, 
and table-top sweeteners, and in 
pharmaceutical preparations including 
tablets, powder mix, and vitamin 
preparations. It enhances flavor systems and 
can be used to mask some unpleasant taste 
characteristics, the approximate sweetening 
power is 180–200 times that of sucrose. 
Unlike some other intense sweeteners, 
aspartame is metabolized in the body . 
Stability and Storage Conditions : Aspartame is stable in dry conditions. In the 
presence of moisture, hydrolysis occurs to 
form the degradation products.  
6.6 MANNITOL 
Description 
 
: Mannitol occurs as white, odorless, crystalline 
powder, or free flowing granules. It has sweet 
taste, approximately sweet as glucose. 
Empirical formula : C6H14O6 
Molecular weight : ≅ 182.17 
Functional category  
 
: Sweetening agent, tablet and capsule diluent, 
tonicity agent, vehicle (vehicle agent) for 
lyophilized preparation. 
Applications in this formulation 
 
: In Pharmaceutical preparation it is primarily used 
as diluent (10-90%) in tablet formulations. 
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6.7 MAGNESIUM STEARATE 
Non proprietary name : BP: magnesium stearate, 
 JP: magnesium stearate, Ph eur:magnesii stearas, 
USPNF: magnesium stearate. 
Synonyms : Magnesium octsdecanoate; octa decanoic 
acid,magnesium salt; stearic acid, magnesium salt 
Chemical name and CAS 
registry number 
: Octadecanoic acid magnesium salt [557-04-0] 
Functional category :  Tablet and capsule lubricant 
Application in pharmaceutical 
formulation or technology 
 
:  Magnesium stearate is widely used in cosmetics, 
foods and in pharmaceutical formulation. It is 
primarily used as a lubricant in capsule and tablet 
manufacture. 
Description : Magnesium stearate is a very fine, light white, 
precipitated or milld, implantable powder of low 
bulk density, having a faint odor of stearic acid 
and a characteristic taste. The powder is greesy to 
the touch and readily adheres to the skin. 
Melting range : 117-150oc(commercial samples); 126-130oc(high 
purity magnesium stearate) 
Solubility : Sractically insoluble in ethanol, ethanol(95%), 
ether and water; slightly soluble in warm benzene 
and warm ethanol(95%) 
6.8 TALC 
Nonproprietary Names :  BP: Purified talc 
 JP: Talc 
 PhEur: Talcum· USP: Talc 
Synonyms 
 
: Altalc; E553b; hydrous magnesium calcium 
silicate; hydrous magnesium silicate; Luzenac 
Pharma; magnesium hydrogen metasilicate; 
Magsil Osmanthus; Magsil Star; powdered talc; 
Chemical Name and CAS 
Registry Number 
: Talc [14807-96-6] 
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Empirical Formula and 
Molecular Weight 
 
: Talc is a purified, hydrated, magnesium silicate, 
approximating to the formula Mg6 
(Si2O5)4(OH)4.  
Description : Talc is a very fine, white to greyish-white, 
odorless, impalpable, unctuous, crystalline 
powder. It adheres readily to the skin and is soft 
to the touch and free from grittiness. 
Functional Category : Anticaking agent; glidant; tablet and capsule 
diluent; tablet and capsule lubricant. 
Applications in Pharmaceutical 
Formulation or Technology 
: Talc was once widely used in oral solid dosage 
formulations as a lubricant and diluent.  
 Stability and Storage Conditions 
 
: Talc is a stable material and may be sterilized by 
heating at 160°C for not less than 1 hour. It may 
also be sterilized by exposure to ethylene oxide 
or gamma irradiation. 
Safety : Talc is used mainly in tablet and capsule 
formulations. Talc is not absorbed systemically 
following oral ingestion and is therefore 
regarded as an essentially nontoxic material. 
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7. EXPERIMENTAL INVESTIGATION 
 
7.1. Preparation of standard graph of Naproxen sodium in distilled water 
Accurately weighed amount (100 mg) of the drug was dissolved in distilled water in 100 
ml volumetric flask and the volume was made up to 100ml. from this stock solution 10ml is 
withdrawn in to volumetric flask, made the volume up to 100ml with distilled water. From this 
2nd stock solution (100mcg/ml), concentrations of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 μg/ml 
solutions were prepared and the corresponding absorbance was measured at 332 nm in a 
UV/Visible spectrophotometer (Figure 1).  
 
7.2. Preparation of standard graph of Naproxen sodium in pH 6.8 phosphate 
buffer 
Accurately weighed amount (100 mg) of the drug  was dissolved in pH 6.8 phosphate 
buffer in 100 ml volumetric flask and the volume was made up to 100ml. from this stock 
solution 10ml is withdrawn in to volumetric flask, made the volume up to 100ml with pH 6.8 
buffer. From this 2nd stock solution (100mcg/ml), concentrations of 10, 20, 30, 40, 50, 60, 70, 
80, 90, 100 μg/ml solutions, were prepared and the corresponding absorbance was measured at 
332 nm in a UV/Visible spectrophotometer (Figure 2).  
 
7.3. Preparation of the tablet formulations by direct compression method 
Each tablet (weight 400mg) consisted of Naproxen sodium, superdisintegrants such as 
crospovidone, croscarmellose sodium, sodium starch glycolate (SSG), low subsituated hydroxyl 
propyl cellulose (L-HPC), mannitol, aspartame, talc and magnesium stearate ,  prepared by 
direct compression method .  The drug, diluent, superdisintegrant, sweetners, are passed through   
the sieve no. 40. All the ingredients are mixed well in the motor.  Then mixed with lubricant (2 
mg) for 3 min in a motor.  The mixer was compressed by using 10mm flat punches on sixteen 
station rotary tablet compression machiene. 
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Table No: 4 General composition of formulation prepared by direct 
compression method 
 
Formulation F1 F2 F3 F4 F5 F6 
Drug 275mg 275mg 275mg 275mg 275mg 275mg 
SSG 16mg 24mg 32mg - - - 
CCS - - - 16mg 24mg 32mg 
Mannitol 103 mg 95 mg 87 mg 103 mg 95 mg 87 mg 
Aspartme 2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 
Magnesium 
stearate 
2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 
Talc 2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 
Total 400mg 400mg 400mg 400mg 400mg 400mg 
SSG = Sodium Starch Glycolate; CCS = Cros Carmellose Sodium. 
 
Table No: 5 General composition of formulation prepared by direct 
compression method 
 
Formulation F7 F8 F9 F10 F11 F12 
Drug 275mg 275mg 275mg 275mg 275mg 275mg 
CP 16mg 24mg 32mg - - - 
L-HPC - - - 16mg 24mg 32mg 
Mannitol 103 mg 95 mg 87 mg 103 mg 95 mg 87 mg 
Aspartme 2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 
Magnesium 
stearate 
2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 
Talc 2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 
Total 400mg 400mg 400mg 400mg 400mg 400mg 
 
CP = Crospovidone; L-HPC = Low- substituted hydroxypropyl cellulose 
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7.4. Characterization of Fast Disintegrating Tablet 
A. Evaluation of blends  
The quality of tablet is generally dictated by the quality of physicochemical properties of 
blends. There are many formulation and process variables involved in mixing step and all these 
can affect the characteristics of blends produced. 
The various characteristics of blends tested are as given below:  
 
1. Angle of Repose  
The frictional force in a loose powder can be measured by the angle of repose θ. It is 
defined as, the maximum angle possible between the surface of the pile of the powder and the 
horizontal plane. If more powder is added to the pile, it slides down the sides of the pile until the 
mutual friction of the particles producing a surface angle θ, is in equilibrium with the 
gravitational force. The angle of repose was determined by the funnel method suggested by 
Newman. Angle of repose is determined by the following formula  
Tan θ = h/r 
Therefore θ = Tan -1 h/r  
      Where        θ = Angle of repose  
                        h = height of the cone  
                        r = Radius of the cone base  
Angle of Repose less than 30 0 shows the free flowing of the material.  
 
2. Bulk Density  
Density is defined as weight per unit volume. Bulk density, ρb , is defined as the mass of 
the powder divided by the bulk volume and is expressed as gm/ cm 3 .  
The bulk density of a powder primarily depends on particle size distribution, particle 
shape and the tendency of particles to adhere together.  
Bulk density is very important in the size of containers needed for handling, shipping, 
and storage of raw material and blend. It is also important in size blending equipment. A 
standard procedure used for obtaining bulk density or its reciprocal bulkiness is given below.  
A sample of about 50 cm 3 (blend) is carefully introduced in a 100ml graduated cylinder. 
The cylinder is dropped onto a hard wood surface three times from a height of 1 inch at two 
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second interval. The bulk density is then obtained by dividing the weight of sample in gms by 
final volume in cm 3 . 
ρb = M/ V p 
Where              ρb = Bulk Density  
                        M = Weight of sample 
                        V p = Final volume of blend in cm 3  
 
3. Tapped density  
It is defined as the ratio of weight of blend in gms to the volume (Tapped volume) in   
cm3.   Tapped density is given by  
Tapped density ρ t = Weight in gms / V b 
Where V t = Tapped volume (Tapped volume)  
 
4. Compressibility Index Hausner’s Ratio  
It is an important measure obtained from bulk density and is defined as,  
C = ρb – ρt / ρb   X 100  
If the bed of particles is more compressible the blend will be less flow able and vice versa. 
Materials having “C” values less then 20 -21% is termed as free flowing materials.  
 
B. Evaluation of fast disintegrating tablet  
Tablets from all the formulation were subjected to following quality control test.  
 
1) General appearance  
The general appearance of a tablet, its visual identity and over all “elegance” is essential 
for consumer acceptance. Include in are tablet’s size, shape, colour, presence or absence of an 
odor, taste, surface texture, physical flaws and consistency and legibility of any identifying 
marking.  
 
2) Thickness of Tablet 
 Randomly 10 tablets were taken from each formulation trial batch and their thickness 
was measured using a Vernier caliperse. The individual tablet was placed between two anvils 
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and sliding knob was rotated until the tablet was tightly fitted. The digital reading displayed was 
noted.  
 
3) Weight variation test 
20 tablets were randomly selected from each formulation trial batch and their average 
weight was calculated using digital balance. Individual weight of each tablet was also calculated 
using the same and compared with the average weight.  
Table No:6 Uniformity of weight 
Average weight of Tablets (mg) Maximum percentage different allowed 
80 or less ±10.1 
80 – 250 ±7.5 
More than 250 ±5.0 
 
4) Hardness 
Tablet hardness, which is defined as the force required to break a tablet by radial 
compression, was measured with a tablet hardness tester (Pfizer/Monsato Hardness tester    
 
5) Friability  
It is measured of mechanical strength of tablets. Roche fribalator is used to determine the 
friability by following procedure.  
Twenty tablets were weighed and placed in Roche Friabilator where the tablets were 
exposed to rolling and repeated shocks resulting from free falls within the apparatus. After 100 
revolutions, tablets are removed, dedusted and weighed again. The friability was determined as 
the percentage loss in weight of the tablets.  
% Friability =( loss in weight / Initial weight )X 100 
 
6) Disintegration Time  
The test is carried out on the 3 tablets using the apparatus specified in USP distilled 
water at 37 0 C ± 2 0 C was used as a disintegration media and the time in second taken for 
complete disinigration of the tablet with no palpable mass remaining in the apparatus was 
measured in seconds. 
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7) Determination of in vivo disintegration time 
A tablet was put into the mouth of a healthy male adult volunteer without water and the 
oral disintegration time was recorded as the time until the volunteer felt that the tablet had 
disappeared in his mouth while moving his tongue (n = 3). 
 
8) Wetting time  
A sample of the final tablet was placed in a Petri dish (10 cm in diameter) containing 10 
ml water at room temperature. The wetting time is that necessary for the complete wetting of the 
tablet. Results of this test, carried out in triplicate, are shown in for the different samples.  
 
9) In vitro dissolution  
Freshly prepared phosphate buffer (pH 6.8) of 900 ml was placed in each dissolution 
vessels of dissolution test apparatus (USP, II paddle method).  The tablets were placed in the 
dissolution medium.  The temperature of the dissolution medium was maintained at 37± 0.50C 
and the paddle was rotated at 50 rpm.  Five ml samples were withdrawn. The sample volume 
was immediately replaced with the same volume of fresh media as when a sample was taken. 
The samples withdrawn were filtered, diluted and estimated spectrophotometrically at 332 nm.  
Cumulative amount of the drug released at each interval was calculated by using standard graph 
of Naproxen sodium. 
 
10) Water absorption ratio  
A small culture Petri dish can be taken containing 6ml of water and a piece of tissue 
paper folded twice is placed. A tablet is placed gently on it and the time for complete wetting is 
measured. The wetted tablet is reweighed. Water absorption ratio R was determined according 
the following equation 
R = (Wa - Wb) /  Wb x100 
Where Wa is the weight of tablet after water absorption and Wb is the weight of tablet before 
absorption. 
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11) Content uniformity 
  From each batch of prepared tablets, ten tablets were collected randomly and powdered. 
A quantity of powder equivalent to weight of one tablet was transferred in to a 100 ml 
volumetric flask, to this 50 ml pH 6.8 buffer of was added and then the solution was subjected to 
sonication for about 2 hrs. The solution was made up to the mark with pH 6.8 buffer. The 
solution was filtered and suitable dilutions were prepared with pH 6.8 buffer. Same 
concentration of the standard solution was also prepared. The drug content was estimated by 
recording the absorbance at 332 nm by using UV-Visible spectrophotometer. 
 
12) Fourier Transform Infrared Spectroscopy 
               In this study, FTIR spectra for the drug and the excipients of the optimized tablets were 
obtained.  One part of Potassium Bromide was mixed with 100 parts of the optimized tablet 
powder and used for the FTIR spectrum.  Pure drug was also mixed with Potassium Bromide 
and spectrum was obtained.  Both spectra were compared for possible deviations.  
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8. RESULTS AND DISCUSSION 
8.1 Preparation of standard graph of Naproxen sodium  
 Naproxen sodium has the maximum absorbance at 332 nm. Standard graph of 
naproxen sodium in water was plotted by taking concentration ranging from 10 to 100 µg/ml 
and a good correlation was obtained with R2 value of 0.9991(Figure No 1). Standard graph 
of Naproxen sodium in pH 6.8 buffer was plotted by taking concentration ranging from 10 to 
100 µg/ml and a good correlation was obtained with R2 value of 0.999 (Figure No 2).  
Table No: 7 Preparation of standard graph of Naproxen sodium in  
   distilled water 
Concentration(mcg/ml) Absorbance(nm) 
0 0 
10 0.022 
20 0.07 
30 0.118 
40 0.17 
50 0.23 
60 0.286 
70 0.33 
80 0.392 
90 0.442 
100 0.505 
 
Figure No: 1 Standard graph of Naproxen sodium in water. 
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Table No: 8 Preparation of standard graph of Naproxen sodium in pH 6.8 
phosphate buffer 
Concentration(µg/ml) Absorbance(nm) 
0 0.000 
10 0.037 
20 0.099 
30 0.150 
40 0.206 
50 0.264 
60 0.312 
70 0.365 
80 0.409 
90 0.462 
100 0.524 
 
 
Figure No: 2 Standard graph of Naproxen sodium in pH 6.8 buffer. 
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8.2 Evaluation of blend 
Blend was evaluated for bulk density, tapped density, compressibility index, hausner 
ratio, angle of repose (Table. No 9 and 10). All the formulation show angle of repose below 
300 that mean they show free flowing property. All the formulation has hausner ratio 
between the 0.7 to 1.5. It indicates all the formulation show better flow property.  
 
Table No: 9 Evaluation of mixed blend of drug and excipients 
Formulation 
Angle of 
repose(θ) 
Bulk 
density 
(gm/cm3) 
Tapped 
density 
(gm/cm3) 
Compressibility  
(%) index (CI) 
Hausner’s 
ratio 
F1 27.61 0.38 0.52 44.51 0.90 
F2 29.42 0.43 0.71 40.22 1.19 
F3 26.30 0.36 0.62 36.41 1.21 
F4 30.02 0.36 0.59 35.44 0.73 
F5 26.81 0.40 0.62 42.35 1.15 
F6 29.34 0.39 0.71 38.12 0.92 
F7 29.71 0.42 0.58 37.21 0.82 
F8 27.56 0.36 0.59 40.65 0.91 
F9 28.41 0.42 0.61 38.71 1.25 
F10 29.22 0.39 0.57 41.34 0.94 
F11 30.01 0.44 0.71 34.92 1.54 
F12 28.78 0.42 0.62 40.33 0.91 
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Table No: 10 Evaluation of Naproxen sodium tablets 
Formulation Thickness 
Hardness 
(kg/cm2) 
Weight 
variation 
Friability 
(%) 
 Disintegration 
Time in Sec. 
Water 
Absorption    
ratio (%) 
F1 4.17±0.05 3.5 400±1.05 0.75 47 98.24 
F2 4.13±0.07 4.1 400±2.5. 0.68 43 111.91 
F3 4.16±0.05 3.2 400±1.5 0.64 49 103.42 
F4 4.15±0.06 4.0 400±2.9 0.61 60 101.92 
F5 4.14±0.09 3.1 400±1.9 0.73 55 99.51 
F6 4.15±0.07 3.5 400±1.6 0.75 50 100.24 
F7 4.17±0.05 3.1 400±1.5 0.79 40 105.23 
F8 4.19±0.07 4.2 400±2.6 0.68 30 106.92 
F9 4.16±0.05 3.5 400±3.1 0.85 35 115.54 
F10 4.15±0.06 3.9 400±2.7 0.79 94 79.31 
F11 4.14±0.09 3.7 400±1.3 0.84 82 78.44 
F12 4.15±0.07 3.2 400±1.6 0.87 87 73.96 
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8.3 Evaluation of tablets 
The total weight of each formulation was not maintained constant however; the 
weight variation of the tablets was within the permissible limits of 5%, as specified for tablet 
weighing more than 400 mg( Table No 11 and 12). 
  The hardness of tablets was tested using hardness tester to find out whether they 
could retain their physical shape. The hardness of the prepared tablets were within the limits. 
Tablet thickness was also used to assess the quality of tablets. Under uniform 
conditions of manufacture, the total weight of tablet and thickness were linearly related. The 
friability loss of less than 0.5 – 1% in weight is generally considered acceptable. 
Disintegration test was conducted for all the formulation. From the results the tablets which 
have crospovidone they show less disintegration time when compared with other 
disintegrants, in addition to its unique particle size and morphology, disintegrant properties 
of CP are not affected by pH and consequently being non-ionc does not bind to ionic drug 
moieties. The probable reason for delayed disintegration of the tablets with cros carmellose 
sodium, sodium starch glycolate, might be due to their tendency to gel more than 
crospovidone . So, it may be assumed that 8% concentration is optimum for crospovidone. 
8%concentration is optimum for cross carmellose. and 4% concentration is optimum for 
sodium starch glycolate, disintegration occurs as a result of up take of water followed by 
rapid and enormous swelling. 4% concentration is optimum for L-subsituated hydroxyl 
propyl cellulose. Such a behaviour of super disintegrants at higher concentration may be due 
to blockade of capillary pores, which prevents the entry of fluid in to the tablet (Table No 11. 
and 12). 
  Water absorption study conducted for all batches crospovidone shoe more water 
absorption ratio. Sodium starch glycolate in second position, Cros carmellose in third 
position. 
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8.4 Content uniformity  
 All the formulations were checked for content uniformity as per Indian 
Pharmacopoeia.  All the formulations passed the test and the percent of active ingredient 
ranged from 94.9-102.1% (Table No 13). 
 
Table No: 11 Assay of Naproxen sodium 
Formulation Assay 
F1 98.5% 
F2 101.1% 
F3 96.4% 
F4 97.2% 
F5 99.1% 
F6 96.4% 
F7 95.7% 
F8 99.7% 
F9 96.8% 
F10 97.1% 
F11 98.7% 
F12 96.4% 
 
8.5 Comparison of Dissolution Profile for F1 to F12 batches 
In vitro dissolution study of formulations F1to F12 batches showed drug release with 
in 10 min, in this F8 batch show good dissolution property (Figure No 3). F8 batch contain 
8% of Crospovidone. 
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Table No: 12 Comparison of dissolution profile for F1, F2, F3 Batches 
(Naproxen sodium+ Sodium starch glycolate) 
Time(min) 
 
F1 Cumulative % 
Drug Release 
F2 Cumulative % 
Drug Release 
F3 Cumulative % Drug 
Release 
0 0 0 0 
2 34.51 30.12 31.47 
4 51.21 46.65 48.72 
6 69.09 66.47 60.52 
8 82.92 83.47 72.15 
10 96.70 91.48 91.42 
 
 
Figure No: 3 Comparison of dissolution of F1, F2, F3 batches. 
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Table No: 13 Comparison of dissolution profile for F4, F5, F6 batches 
   (Naproxen sodium+ Cros carmellose sodium) 
Time(min) 
 
F4 Cumulative % 
Drug Release 
F5 Cumulative % 
Drug Release 
F6 Cumulative % 
Drug Release 
0 0 0 0 
2 42.19 45.59 48.87 
4 53.91 59.18 62.72 
6 61.24 72.55 76.16 
8 73.59 85.92 89.48 
10 95.09 95.18 95.72 
 
 
 
Figure No: 4 Comparison of dissolution of F4, F5, F6 batches. 
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Table No: 14 Comparison of dissolution profile for F7, F8, F9 batches  
  (Naproxen sodium+ Crospovidone) 
Time(min) 
 
F7 Cumulative % 
Drug Release 
F8 Cumulative % 
Drug Release 
F9 Cumulative % 
Drug Release 
0 0 0 0 
2 49.25 46.60 45.09 
4 63.55 63.71 62.72 
6 77.36 78.83 76.31 
8 88.30 86.49 85.48 
10 94.55 97.32 96.12 
 
 
 
Figure No: 5 Comparison of dissolution of F7, F8, F9 batches. 
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Table No: 15 Comparison of dissolution profile for F10, F11, F12 batches 
(Naproxen sodium+ L-HPC) 
Time(min) 
 
F10 Cumulative % 
Drug Release 
F11 Cumulative % 
Drug Release 
F12 Cumulative % 
Drug Release 
0 0 0 0 
2 36.85 36.56 37.89 
4 52.46 53.26 56.64 
6 68.85 67.51 67.69 
8 86.45 85.56 83.75 
10 95.45 93.86 90.71 
12 98.89 97.12 94.82 
 
 
Figure No: 6 Comparison of dissolution of F10, F11, F12 batches. 
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8.6 Comparison of dissolution profile for F1, F6, F8, F10 batches 
In vitro dissolution study of formulation F8 batch release the drug 97.32with in 10 
min and other batches showed (Figure No 7) less percentage of drug release than F8 batches 
(Table No 16). 
 
Table No: 16 Comparison of dissolution profile for F1, F6, F8, F10 batches 
Time(min) 
 
F1 
Cumulative % 
drug release 
F6 
Cumulative % 
drug release 
F8 
Cumulative % 
drug release 
F10 
Cumulative % 
drug release 
0 0 0 0 0 
2 34.51 48.87 46.60 36.85 
4 51.21 62.72 63.71 52.46 
6 69.09 76.16 78.83 68.85 
8 82.92 89.48 86.49 86.45 
10 96.70 95.72 97.32 95.45 
12 - - - 98.89 
 
 
Figure No: 7 Comparison of dissolution of F1, F6, F8, F 10 batches. 
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8.7  Comparison of water absorption ratio (%) of F1, F6, F8, F10  batches 
Water absorption ratio (%) of F8 batch was showed the maximum water absorption 
ratio (%) than other batches (Figure No 8). 
 
Formulation Water Absorption     ratio (%) 
F1 98.24 
F6 100.24 
F8 106.91 
F10 79.32 
 
Figure No: 8 Water absorption ratios (%) of F1, F6, F8, F10 batches. 
 
 
8.8 Fourier transform infrared spectroscopy 
          The IR spectra of pure Naproxen sodium drug showed the characteristic absorption 
bands are as follows: COO- at 1585 cm-1, aromatic CH3- CH stretching at 2957 cm-1, 
aliphatic CH3O stretching at 2904 cm-1, C-H stretching of aromatic ring at 3058 cm-1, 
carboxyl keto group showed absorption band at 1631 cm-1, naphthalene stretching at 1500 
cm-1 and strong bending mode at 900-650 cm-1.  
 No drug-polymer interaction was observed in the FTIR spectra of the powder mixture 
of optimized formulation since the absorption peaks of the drug still could be detected in the 
mixture.
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Figure No: 9 FTIR STUDIES ON NAPROXEN SODIUM 
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Fig. No: 10 FTIR STUDIES ON DESCRIPTION PLACED OF 
NAPROXEN SODIUM FDT 
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Fig. No: 11 FTIR STUDIES ON OPTIMIZED FORMULATION OF 
NAPROXEN SODIUM FDT 
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9. STABILITY STUDY OF TABLET BATCH  
 
The batch F8 are selected as an optimum batch and the stability study was carried out at 
accelerated condition of 400C, 75 % RH condition for a period of three months. 
Method: 
                  The tablets were individually wrapped using Aluminium foil and packed in ambered 
color screw cap bottle and put at above specified condition in incubator for 3 months. After 
three months tablets were evaluated for content uniformity and In-vitro drug release. 
Observation: 
                    The results of stability study after 3 months are given in Table. No: 19. 
The plot of Cumulative percentage Drug release v/s Time deplicated in Fig. No: 12. 
Drug content: 
                     Comparative content uniformity of the tablet after 3 months stability.  
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Table No: 17 Dissolution Profile of batch F8 kept for stability of Three 
months 
 
 
 
Dissolution medium 
900ml 0.1N HCL 
Time in 
(minutes) 
Cumulative % drug release 
Initial 3 Months 
F8 F8 
5 73.60 72.65 
10 97.32 96.89 
20 94.83 94.12 
30 92.95 91.98 
45 92.93 91.88 
       
Fig No: 12 Dissolution profile of F8 Initial and Three Months 
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10.  SUMMARY & CONCLUSION 
Fast disintegrating tablets of Naproxen sodium prepared by direct compression method 
The in vitro drug release from formulation containing superdisintegrant SSG was found 
between 87.64 to 96.70 in 10 min and the maximum drug release was found with F1 
formulation. The in vitro drug release from formulation containing superdisintegrant CCS 
was found between 94.20 to 95.72 in 10 min and the maximum drug release with F6 
formulation. The in vitro drug release from formulation containing superdisintegrant CP was 
found between 90.75 to 97.32 in 10 min and the maximum drug release with F8formulation. 
The in vitro drug release from formulation containing superdisintegrant L-HPC was found 
between 94.82 to 98.89 in 12 min and the maximum drug release with F10 formulation. 
Fast disintegrant tablets transform into easy-to-swallow suspension on contact with the 
saliva, after ingested in mouth. These are particularly useful for pediatric or geriatric 
patients, can be taken without liquids. The developed formulations have suitable 
characteristics. Among the four superdisintegrants, Crospovidone (F8) showed good 
disintegrants property. It has also shown good water absorption ratio. 
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